46 allée d’Italie
69007 Lyon
Phone: +33 (0) 4 72 72 87 17

Alexandre Fraichard, CEO
Privately Held


Founded in March 1999, genOway SA, which uses technology based on embryonic stem cell research and genetic engineering, is a tool provider in the field of functional genomics that develops and markets research models for both in vitro and in vivo research of drug targets.

The company provides drug development services to the pharmaceutical industry, from cloning the gene of interest, target vector construction and homologous recombination to producing homozygous animals, allowing its customers to concentrate on analyzing and understanding the phenotype.

genOway is investing in the development of new research tools, which eventually will enable it to offer cell and animal models that will speed up research and correspond more closely to scientific requirements. Tool development includes work in the areas of conditional and inducible systems and in vitro tools, and the creation of an expression site bank to develop tissue-specific overexpression models.


In February 2001, genOway and SYN X Inc. entered into a collaboration agreement to develop cardiovascular and central nervous system drug targets. genOway and Lyons University partner to develop common research programs. The company also has signed an exclusive mutual partnership for Europe with Charles River Laboratories to supply genOway with all the animals it requires for its research.